By Marcia Dunn

NASA held its first public meeting on UFOs Wednesday a year after launching a study into unexplained sightings.

The space agency televised the hourslong hearing featuring an independent panel of experts. The team includes 16 scientists and other experts selected by NASA including retired astronaut Scott Kelly, the first American to spend nearly a year in space.

Several committee members have been subjected to “online abuse” for serving on the team, which detracts from the scientific process, said NASA's Dan Evans, adding that NASA security is dealing with it.

“It’s precisely this rigorous, evidence-based approach that allows one to separate the fact from fiction," Evans said.

The study is a first step in trying to explain mysterious sightings in the sky that NASA calls UAPs, or unidentified aerial phenomena.

The group is looking at what unclassified information is available on the subject and how much more is needed to understand what's going on in the sky, according to astrophysicist David Spergel, the committee's chair who runs the Simons Foundation.

No secret military data are included, such as anything surrounding the suspected spy balloons from China spotted flying over the U.S. earlier this year.

The meeting was held at at NASA headquarters in Washington with the public taking part remotely.

A final report is expected by the end of July.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Share:
More In Science
As U.S. Opioid Crisis Worsens, Price of Life-Saving Drug Naloxone Skyrockets
Jill Wagner and Baker Machado break down the state of the Opioid Crisis in the U.S. The CDC reported a 30% increase in overdose deaths from 2020 to 2021, but in recent months pharmaceutical companies have drastically raised the price of Naloxone or 'Narcan,' affecting the response of community harm prevention groups.
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Legal Questions Swirl as States Push Back Against Biden COVID Vaccine Mandate
The Biden Administration's mandate for COVID vaccinations by large employers has been put on hold by federal courts as GOP-led states and some businesses push back on the order's legality. Jonathan Adler, a law professor at Case Western Reserve University, joined Cheddar to discuss the legal challenges to implementing such mandates through OSHA (Occupational Safety and Health Administration). "Certainly expanding vaccinations is a good thing, and as vaccination rates go up that's better for all of us," Adler said. "But there are some legal questions about whether or not it's appropriate to use a law about occupational safety and health as the means to do that."
What COVID-19 Vaccines for Kids Might Mean for Fight Against Pandemic
Dr. Robert Frenck, an infectious disease specialist at Cincinnati Children's Hospital, joined Cheddar to talk about the significance of children ages 5-11 being authorized to receive COVID-19 vaccinations. He also discussed schools being cleared to administer vaccines and noted the importance of meeting people where they are rather than forcing them to find the shots. Frenck also said he expects that children under 5 years old will begin getting vaccinations sometime in spring.
Everything You Need to Know About Child Covid-19 Vaccines
A CDC advisory committee as unanimously voted to recommend the Pfizer Covid-19 vaccine in children ages 5 to 11. Dr. Amesh Adalja, Infectious Disease Specialist and Senior Scholar at Johns Hopkins Center for Health Security, joined Cheddar News to discuss.
Load More